title: Visceral Kaposi's sarcoma remission after intestinal transplant. First case report and systematic literature review.
abstract: BACKGROUND
  Kaposi's sarcoma (KS) is an infrequent vascular neoplasm commonly diagnosed as an isolated cutaneous lesion that can involve other organs. So far, there are no data in the literature about the development of KS after intestinal transplant.
  
  
  METHODS
  In this study, the authors describe a case of "visceral KS" with pulmonary and intestinal involvement and perform a systematic literature review of case reports and single-center series identified in MEDLINE.
  
  
  RESULTS
  This case was a 42-year-old man, diagnosed with visceral KS 9 months after receiving an isolated intestinal transplant. He was successfully treated with a combination of sirolimus and liposomal doxorubicin and achieved an 18-month disease-free survival. A total of 54 cases from 27 manuscripts and the present case were analyzed in this study. The mean time from transplant to diagnosis was 17.2 months. Lungs and gastrointestinal tract were the main organs involved. Immunosuppressants were discontinued in two of the three (66.7%) cases, and sirolimus was added in eight cases. Doxorubicin was used in 12 cases. In a univariate analysis, the use of Tacrolimus, type of transplant, and presence of cutaneous KS seem to be the significant predictors of response to therapy and survival; the addition of doxorubicin showed a reduction in graft loss.
  
  
  CONCLUSIONS
  Treatment of KS in posttransplant patients should be designed aiming to obtain a complete response, irrespective of the organ affected. Only recipients who are able to achieve a sustained response would be able to obtain long-term disease-free survival.
authors.affiliation: Unidad de Hepatología, Cirugía Hepatobiliar y Transplante Hepático-Unidad de Nutrición, Rehabilitación y Transplante Intestinal, Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina.
authors.forename: Francesco
authors.initials: F
authors.lastname: D'Amico
authors.forename: Claudia
authors.initials: C
authors.lastname: Fuxman
authors.forename: Fabio
authors.initials: F
authors.lastname: Nachman
authors.forename: Lisandro
authors.initials: L
authors.lastname: Bitetti
authors.forename: Martin
authors.initials: M
authors.lastname: Fauda
authors.forename: Constanza
authors.initials: C
authors.lastname: Echevarria
authors.forename: Hector
authors.initials: H
authors.lastname: Solar
authors.forename: Pedro
authors.initials: P
authors.lastname: Politi
authors.forename: Ana
authors.initials: A
authors.lastname: Cabanne
authors.forename: Eduardo
authors.initials: E
authors.lastname: Mauriño
authors.forename: Andres
authors.initials: A
authors.lastname: Ruf
authors.forename: Gabriel E
authors.initials: GE
authors.lastname: Gondolesi
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007422:Intestines / Q000637:transplantation*; D008297:Male; D012008:Recurrence; D012514:Sarcoma, Kaposi / Q000601:surgery*; D020123:Sirolimus / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D004317:Doxorubicin; D020123:Sirolimus